Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta

Pukhraj Rishi, Ekta Rishi, Anusha Venkatraman

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

A 12-year-old girl, diagnosed of osteogenesis imperfecta, presented with sudden visual loss in the left eye. Investigations revealed an active choroidal neovascular membrane. She underwent treatment with intravitreal Bevacizumab (1.25 mg/0.05 ml). Follow-up at 1 month revealed the development of lacquer crack running through the macula, underlying the fovea. The patient received two re-treatments at 1-month intervals, following which the choroidal neovascularization (CNV) regressed completely. However, further progression of lacquer cracks was noted. At the last follow-up, 6 months following the last injection, the fundus remained stable and vision was maintained at 20/200. Considering the natural history of the disease and the increased risk of rupture of the Bruch's membrane in such eyes, the possible complication of a lacquer crack developing must be borne in mind, before initiating treatment.

Original languageEnglish (US)
Pages (from-to)229-231
Number of pages3
JournalIndian Journal of Ophthalmology
Volume60
Issue number3
DOIs
StatePublished - May 2012
Externally publishedYes

Keywords

  • Bevacizumab
  • choroidal neovascularization
  • lacquer crack
  • osteogenesis imperfecta

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta'. Together they form a unique fingerprint.

Cite this